SELEX methods on the road to protein targeting with nucleic acid aptamers

Bayat, Payam; Nosrati, Rahim; Alibolandi, Mona; Rafatpanah, Houshang; Abnous, Khalil; Khedri, Mostafa; Ramezani, Mohammad

doi:10.1016/j.biochi.2018.09.001

Cited by 194 publications

(116 citation statements)

References 220 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…In theory, aptamers can be produced against any type of targets, from small inorganic and organic molecules to cells and to whole organisms such parasites, but in practical situations, it is sometimes difficult to obtain high-specific and high-affinity aptamers to some targets [32]. For instance, it is difficult to select aptamers against negatively charged targets because oligonucleotide strands have negative charges on their backbone [33]. The low molecular weight of aptamers is both advantageous and disadvantageous in terms of in vivo application.…”

Section: Aptamers Mabsmentioning

confidence: 99%

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

Xiang

2020

IJMS

100

View full text Add to dashboard Cite

The arrival of the monoclonal antibody (mAb) technology in the 1970s brought with it the hope of conquering cancers to the medical community. However, mAbs, on the whole, did not achieve the expected wonder in cancer therapy although they do have demonstrated successfulness in the treatment of a few types of cancers. In 1990, another technology of making biomolecules capable of specific binding appeared. This technique, systematic evolution of ligands by exponential enrichment (SELEX), can make aptamers, single-stranded DNAs or RNAs that bind targets with high specificity and affinity. Aptamers have some advantages over mAbs in therapeutic uses particularly because they have little or no immunogenicity, which means the feasibility of repeated use and fewer side effects. In this review, the general properties of the aptamer, the advantages and limitations of aptamers, the principle and procedure of aptamer production with SELEX, particularly the undergoing studies in aptamers for cancer therapy, and selected anticancer aptamers that have entered clinical trials or are under active investigations are summarized.

show abstract

Section: Aptamers Mabsmentioning

confidence: 99%

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

Xiang

2020

IJMS

100

View full text Add to dashboard Cite

show abstract

“…Finally, the resulting pool is sequenced, and the selected aptamers are characterized for their binding affinity. Since the first introduction of the SELEX method in 1990 by two independent groups [24,25], a large number of aptamers have been developed for various targets ranging from small molecules [26,27] to proteins [28,29], whole cells [30], and tissues [31,32].…”

Section: Principles Of Aptamer Selectionmentioning

confidence: 99%

A Bottom-Up Approach for Developing Aptasensors for Abused Drugs: Biosensors in Forensics

et al. 2019

View full text Add to dashboard Cite

Aptamer-based point-of-care (POC) diagnostics platforms may be of substantial benefit in forensic analysis as they provide rapid, sensitive, user-friendly, and selective analysis tools for detection. Aptasensors have not yet been adapted commercially. However, the significance of the applications of aptasensors in the literature exceeded their potential. Herein, in this review, a bottom-up approach is followed to describe the aptasensor development and application procedure, starting from the synthesis of the corresponding aptamer sequence for the selected analyte to creating a smart surface for the sensitive detection of the molecule of interest. Optical and electrochemical biosensing platforms, which are designed with aptamers as recognition molecules, detecting abused drugs are critically reviewed, and existing and possible applications of different designs are discussed. Several potential disciplines in which aptamer-based biosensing technology can be of greatest value, including forensic drug analysis and biological evidence, are then highlighted to encourage researchers to focus on developing aptasensors in these specific areas.

show abstract

“…Aptamers have high affinity and specificity to their target molecules, similar to antigen-antibody interaction [7], therefore, they are also called "chemical antibodies". Aptamers offer advantages over antibodies including smaller size, higher pH and thermal stability, lower immunogenicity and toxicity, better tissue penetration, lower synthesis costs and easier conjugation or modification [8]. In addition to their widespread use as stand-alone affinity binding reagents in analytical chemistry, aptamers have been engineered into a variety of ligand-specific biosensors, termed aptasensors [9].…”

Section: Introductionmentioning

confidence: 99%

SELEX tool: a novel and convenient gel-based diffusion method for monitoring of aptamer-target binding

et al. 2020

View full text Add to dashboard Cite

Background: Aptamers, single-stranded DNAs or RNAs, can be selected from a library containing random sequences using a method called Systematic Evolution of Ligands by EXponential Enrichment (SELEX). In SELEX, monitoring the enriching statuses of aptamer candidates during the process is a key step until today. Conformational change of an aptamer caused by target-binding in gel can be used to indicate its statuses of binding. Results: In this study, an easy-to-implement gel-based diffusion method (GBDM) was developed to monitor the interaction between enriched aptamer candidates and their targets. In order to prove the concept, characterization of aptamers targeting their targets including protein (thrombin) and non-protein molecules (acetamiprid, ATP, atrazine, profenofos and roxithromycin), respectively, were performed using mini gels. Our method has advantages over the common methods including easy performed with labor-and time-saving in experimental operation. The concept has been proven by monitoring enrichment of dynamic aptamer candidate libraries targeting a small molecule 2,2-bis(4-chlorophenyl) acetic acid (DDA) during SELEX process. A mini gel cassette was designed and fabricated by our laboratory to make mini agarose gels for diffusion with different directions. Conclusions:These results indicate that GBDM, in particular, chasing diffusion is suitable for monitoring the interaction between enriched aptamer candidates and their targets. These pioneering efforts are helpful for novel aptamer selection by breaking through the technical bottleneck of aptamer development and helpful for development of novel aptasensors.

show abstract

SELEX methods on the road to protein targeting with nucleic acid aptamers

Cited by 194 publications

References 220 publications

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

A Bottom-Up Approach for Developing Aptasensors for Abused Drugs: Biosensors in Forensics

SELEX tool: a novel and convenient gel-based diffusion method for monitoring of aptamer-target binding

Contact Info

Product

Resources

About